Integrating phosphoproteomics into the clinical management of prostate cancer

Phosphoproteomic analysis of tumor samples has the potential to uncover significant insights into kinase signaling networks present in late stage prostate cancer that are complementary to genomic and transcriptomic approaches. Phosphoproteomics could potentially aid drug development in clinical tria...

Full description

Saved in:
Bibliographic Details
Published inClinical and translational medicine Vol. 6; no. 1; pp. 1 - 6
Main Authors Cheng, Larry C., Tan, Victor M., Ganesan, Shridar, Drake, Justin M.
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 14.02.2017
John Wiley & Sons, Inc
Subjects
Biomarkers
Clinical bioinformatics
Clinical diagnostics
Clinical trial design
Commentary
Kinase inhibitors
Mass spectrometry
Medicine
Medicine & Public Health
Pharmacotherapy
Phosphoproteomics
Precision medicine
Prostate cancer
Phosphoproteomics
Precision medicine
Biomarkers
Pharmacotherapy
Clinical trial design
Kinase inhibitors
Prostate cancer
Mass spectrometry
Clinical diagnostics
Online AccessGet full text

Cover

More Information
Summary:Phosphoproteomic analysis of tumor samples has the potential to uncover significant insights into kinase signaling networks present in late stage prostate cancer that are complementary to genomic and transcriptomic approaches. Phosphoproteomics could potentially aid drug development in clinical trial design as well as provide utility for oncologists in the personalized therapeutic management of individual cancers through identifying novel biomarkers and druggable targets. Rapid advancement of targeted mass spectrometry platforms is underway to integrate phosphoproteomic technology with genomic assays to soon translate this information into the cancer clinic.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:2001-1326
2001-1326
DOI:10.1186/s40169-017-0138-5